Plain-English translation of NCT03686124 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer treatment called IMA203 or IMA203CD8, which uses your own white blood cells. Doctors take your cells, modify them in a laboratory to recognize your cancer, and then infuse them back into your body to fight the disease. Some patients may also receive a second medication called , which helps boost the immune system.
Current treatments don't work for everyone with advanced solid tumors, and some patients run out of options. This trial explores whether training your own immune cells to target cancer could offer hope to people whose cancers have stopped responding to standard care.
You likely qualify if…
You likely don't qualify if…
First, doctors will test your blood and tumor to see if you're eligible. If you qualify, they'll collect some of your white blood cells through a procedure called leukapheresis. Your cells are then modified in a laboratory over several weeks. When ready, you'll be hospitalized briefly to receive chemotherapy to prepare your body, then receive an infusion of your modified cells. You'll have regular follow-up visits and monitoring for up to 5 years after the infusion.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States